局部栓塞联合靶向免疫综合治疗肝肉瘤样癌1例报告

雷进; 张林枝; 陆荫英; 陈博文; 左石

doi:10.3969/j.issn.1001-5256.2022.04.026

局部栓塞联合靶向免疫综合治疗肝肉瘤样癌1例报告

DOI: 10.3969/j.issn.1001-5256.2022.04.026

雷进¹,
张林枝²,
陆荫英^{1, 2, 3},
陈博文³,
左石^{1, 4, , ,}

1.
贵州医科大学临床医学院，贵阳 550004
2.
解放军总医院第五医学中心肝病医学部，北京 100039
3.
北京大学三〇二临床医学院，北京 100039
4.
贵州医科大学附属医院肝胆外科，贵阳 550004

基金项目:

贵州省优秀青年科技人才专项基金 (Talents of Guizhou Kehe platform[2019]5647)

伦理学声明：本例报告已获得患者知情同意。

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：雷进负责资料分析，撰写论文；张林枝、陈博文负责提出具体修改意见并进行修改；左石、陆荫英负责拟定撰写思路，指导文章写作并最终定稿。

详细信息

通信作者:
左石，drzuoshi@qq.com

计量
- 文章访问数: 662
- HTML全文浏览量: 239
- PDF下载量: 50
- 被引次数: 0
出版历程
- 收稿日期: 2021-07-24
- 出版日期: 2022-04-20

Local embolization combined with targeted comprehensive immunotherapy in treatment of sarcomatoid hepatocellular carcinoma: A case report

Jin LEI¹,
Linzhi ZHANG²,
Yinying LU^{1, 2, 3},
Bowen CHEN³,
Shi ZUO^{1, 4
, ,
,}

1.
School of Clinical Medicine, Guizhou Medical University, Guiyang 550004, China
2.
Department of Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
3.
Peking University 302 Clinical Medical School, Beijing 100039, China
4.
Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China

Research funding:

Special Fund for Outstanding Young Scientific and Technological Talents of Guizhou Province (Talents of Guizhou Kehe platform[2019]5647)

More Information

Corresponding author: ZUO Shi, drzuoshi@qq.com(ORCID: 0000-0001-9092-8723)

摘要

- 肝肿瘤 /
- 肉瘤样癌 /
- 免疫检查点抑制剂
- Liver Neoplasms /
- Sarcomatoid Carcinoma /
- Immune Checkpoint Inhibitors

HTML全文

图 1 肝穿刺病理结果

注：a，见多个核大深染肿瘤细胞，部分成梭形(HE染色，×100)；b，Vimentin弥漫强阳性(免疫组化，×200)；c，CK弥漫强阳性(免疫组化，×200)。

Figure 1. Pathological results of liver puncture

下载: 全尺寸图片幻灯片

图 2 肝脏增强MRI初诊结果

注：a，动脉期呈不均匀轻中度强化；b，门静脉期呈不均匀稍低信号；c，稍长T₂信号病变；d，DWI轻度高信号。箭头指向均表示HSC病灶。

Figure 2. Results of initial diagnosis of liver enhanced MRI

下载: 全尺寸图片幻灯片

图 3 MRI复查结果

注：a，动脉期边缘少许强化，大部未见强化；b，门静脉期病灶边缘呈稍低信号；c，病灶边缘稍长T₂信号病变；d，病灶边缘DWI轻度高信号。箭头表示原病灶边缘异常情况。

Figure 3. Results of MRI reexamination

下载: 全尺寸图片幻灯片

图 4 肝动脉造影结果

注：a，2021年1月20日第1次肝动脉造影，动脉期肝右动脉远端分支增粗，可见肿瘤血管。b，2021年3月1日第2次肝动脉造影，动脉期肝右动脉远端分支增粗，可见肿瘤血管，但较第1次造影明显减少。c，2021年4月23日第3次肝动脉造影，动脉期肝右动脉肿瘤血管减少。d，2021年4月23日第3次介入术后，未见明显肿瘤血管。箭头均指示肝脏肿瘤血管造影情况。

Figure 4. Results of hepatic arteriography

下载: 全尺寸图片幻灯片

参考文献(20)

[1]	WU L, TSILIMIGRAS DI, FAROOQ A, et al. Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: A population-based analysis[J]. Cancer, 2019, 125(21): 3767-3775. DOI: 10.1002/cncr.32396.
[2]	GIANNIS D, MORSY S, GEROPOULOS G, et al. The epidemiology, staging and outcomes of sarcomatoid hepatocellular carcinoma: A SEER population analysis[J]. In Vivo, 2021, 35(1): 393-399. DOI: 10.21873/invivo.12270.
[3]	KIM SJ, RHU J, KIM JM, et al. Surgical treatment outcomes of primary hepatic sarcomas: A single-center experience[J]. World J Hepatol, 2021, 13(5): 584-594. DOI: 10.4254/wjh.v13.i5.584.
[4]	ZHANG H, CHAI S, CHEN L, et al. MRI features of hepatic sarcomatoid carcinoma different from hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Front Oncol, 2021, 11: 611738. DOI: 10.3389/fonc.2021.611738.
[5]	WANG QB, CUI BK, WENG JM, et al. Clinicopathological characteristics and outcome of primary sarcomatoid carcinoma and carcinosarcoma of the liver[J]. J Gastrointest Surg, 2012, 16(9): 1715-1726. DOI: 10.1007/s11605-012-1946-y.
[6]	LI Z, WU X, BI X, et al. Clinicopathological features and surgical outcomes of four rare subtypes of primary liver carcinoma[J]. Chin J Cancer Res, 2018, 30(3): 364-372. DOI: 10.21147/j.issn.1000-9604.2018.03.08.
[7]	FORBES A, PORTMANN B, JOHNSON P, et al. Hepatic sarcomas in adults: A review of 25 cases[J]. Gut, 1987, 28(6): 668-674. DOI: 10.1136/gut.28.6.668.
[8]	KIM DK, KIM BR, JEONG JS, et al. Analysis of intrahepatic sarcomatoid cholangiocarcinoma: Experience from 11 cases within 17 years[J]. World J Gastroenterol, 2019, 25(5): 608-621. DOI: 10.3748/wjg.v25.i5.608.
[9]	MORISUE R, KOJIMA M, SUZUKI T, et al. Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses[J]. Int J Cancer, 2021, 149(3): 546-560. DOI: 10.1002/ijc.33545.
[10]	ERIGUCHI N, AOYAGI S, OKUDA K, et al. Unusual liver carcinomas with sarcomatous features: Analysis of four cases[J]. Surg Today, 2001, 31(6): 530-533. DOI: 10.1007/s005950170116.
[11]	CHENG JY, WANG CH, CHEN JH, et al. Sarcoma- toid carcinomas of the liver, gallbladder, and pancreas: A clinicopathological portrait and literature review[J]. J Clin Hepatol, 2020, 36(10): 2270-2273. DOI: 10.3969/j.issn.1001-5256.2020.10.022. 程捷瑶, 王沧海, 陈建宏, 等. 肝胆胰肉瘤样癌的临床病理特征及文献复习[J]. 临床肝胆病杂志, 2020, 36(10): 2270-2273. DOI: 10.3969/j.issn.1001-5256.2020.10.022.
[12]	LUO C, XIN H, YIN D, et al. Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma[J]. Aging (Albany NY), 2021, 13(11): 15126-15138. DOI: 10.18632/aging.203076.
[13]	QIAN XH, GAO BQ, WANG WL. Primary hepatic sarcomatous carcinoma misdiagnosed as liver abscess: A case report[J]. J Clin Hepatol, 2020, 36(1): 158-160. DOI: 10.3969.j.issn.1001-5256.2020.01.035 钱晓晖, 高炳强, 王伟林. 原发性肝肉瘤样癌误诊为肝脓肿1例报告[J]. 临床肝胆病杂志, 2020, 36(1): 158-160. DOI: 10.3969.j.issn.1001-5256.2020.01.035.
[14]	YANG Z, LV K, ZHAO Y, et al. Sarcomatoid hepatocellular carcinoma mimicking hepatic abscess: A case report[J]. Medicine (Baltimore), 2020, 99(39): e22489. DOI: 10.1097/MD.0000000000022489.
[15]	SHAH V, ARORA A, TYAGI P, et al. Intrahepatic cholangiocarcinoma masquerading as liver abscess[J]. J Clin Exp Hepatol, 2015, 5(1): 89-92. DOI: 10.1016/j.jceh.2014.12.006.
[16]	CHEN LD, RUAN SM, LIANG JY, et al. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound[J]. World J Gastroenterol, 2018, 24(33): 3786-3798. DOI: 10.3748/wjg.v24.i33.3786.
[17]	WEITZ J, KLIMSTRA DS, CYMES K, et al. Management of primary liver sarcomas[J]. Cancer, 2007, 109(7): 1391-1396. DOI: 10.1002/cncr.22530.
[18]	WU Z, WEI Y, CAI Z, et al. Long-term survival outcomes of undifferentiated embryonal sarcoma of the liver: A pooled analysis of 308 patients[J]. ANZ J Surg, 2020, 90(9): 1615-1620. DOI: 10.1111/ans.15684.
[19]	HOOS A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations[J]. Nat Rev Drug Discov, 2016, 15(4): 235-247. DOI: 10.1038/nrd.2015.35.
[20]	ZHU SG, LI HB, YUAN ZN, et al. Achievement of complete response to nivolumab in a patient with advanced sarcomatoid hepatocellular carcinoma: A case report[J]. World J Gastrointest Oncol, 2020, 12(10): 1209-1215. DOI: 10.4251/wjgo.v12.i10.1209.